Follow the RemeGen Co., Ltd. - H Shares share price and the full directors' dealings record of the company, a publicly traded company based in Hong Kong. Shares are listed on the HK market, under the authority of HKEX. Market capitalisation: €6.8bn. The latest transaction was disclosed on 24 July 2026 (Sale). Among the most active insiders: Fang Jianmin. All data is openly available.
47
Insider Decl.
n/a
Thresholds
n/a
26 ops.
Buy Volume
€1m
12 ops.
Sell Volume
22Σ signal
Buys n/a€1m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 2,919 of 29,024 companies
73.8
score / 100
Value
65
Quality
82
FCF yld-2.4%
Earn yld12%
EV/EBITDA7.6x
ROE109%
Gross mgn87%
Net mgn22%
Debt/EBITDA2.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
RemeGen Co., Ltd. is a Chinese biopharmaceutical company focused on the research and development of innovative treatments for cancer and other autoimmune diseases. It is listed on the H-share market.